

***IN THE UNITED STATES PATENT AND TRADEMARK OFFICE***

Applicant: LeGrand et al.  
Title: Azetidine Derivatives as CCR-3  
Receptor  
Appl. No.: 10/507,139  
Filing Date: September 9, 2004  
Patent No.: 7,288,537  
Issue Date: October 30, 2007  
Examiner: Susannah Lee Chung  
Art Unit: 1626  
Confirmation Number: 8975

**PETITION REGARDING PATENT TERM ADJUSTMENT**  
**UNDER C.F.R. §1.705(d)**

Mail Stop PATENT EXT.  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with Applicants duty of candor and good faith of the U.S. Patent and Trademark Office (hereinafter, the "Office"), Applicants note that a reply in regards to the Communication Regarding Patent Term Adjustment is submitted via EFS-Web.

In view of the above statements of fact, Applicants believe they are entitled to 153 days of PTE. The adjustment is based upon 259 days of PTO delay to issuance of 1<sup>st</sup> Office Action on merits less the sum of Applicant's 106 days of delay (e.g. 77 days for Response to 1<sup>st</sup> Office Action and 29 days for late payment of Issue Fee).

An Issue Notification was mailed on October 10, 2007 noting that the current Patent Term Adjustment is now "138" days. This petition requests that the Office review applicants' submission and make the appropriate adjustments to the patent term.


**CONCLUSION**

In view of the above statements of fact, Applicants believe they are entitled to 153 days of Patent Term Extension, based on the following adjustments: 259 days PTO (time for 1<sup>st</sup> Action on merits) less 106 days (sum of days corresponding to Response to 1<sup>st</sup> Office Action (77) and payment of Issue Fee (28)).

It is hereby requested that the Patent Office verify the calculation of the Patent Term Adjustment for the present application.

Patentee requests a waiver of any additional fees required for filing this petition. However, the Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-4409. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-4409.

Respectfully submitted,

  
\_\_\_\_\_  
John Alexander  
Attorney for Applicant  
Reg. No. 48,399

Novartis Institutes for BioMedical Research, Inc.  
400 Technology Square  
Cambridge, MA 02139

(617) 871-3105

Date:

20 Dec 2007